115 related articles for article (PubMed ID: 24880753)
1. Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.
Cruz HG; Hay JL; Hoever P; Alessi F; te Beek ET; van Gerven JM; Dingemanse J
Eur Neuropsychopharmacol; 2014 Aug; 24(8):1257-68. PubMed ID: 24880753
[TBL] [Abstract][Full Text] [Related]
2. Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant.
Hoch M; van Gorsel H; van Gerven J; Dingemanse J
J Clin Pharmacol; 2014 Sep; 54(9):979-86. PubMed ID: 24691844
[TBL] [Abstract][Full Text] [Related]
3. Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects.
Hoever P; Hay J; Rad M; Cavallaro M; van Gerven JM; Dingemanse J
J Clin Psychopharmacol; 2013 Jun; 33(3):363-70. PubMed ID: 23609389
[TBL] [Abstract][Full Text] [Related]
4. Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans.
Hoch M; Hay JL; Hoever P; de Kam ML; te Beek ET; van Gerven JM; Dingemanse J
Eur Neuropsychopharmacol; 2013 Feb; 23(2):107-17. PubMed ID: 22658401
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
Cruz HG; Hoever P; Chakraborty B; Schoedel K; Sellers EM; Dingemanse J
CNS Drugs; 2014 Apr; 28(4):361-72. PubMed ID: 24627301
[TBL] [Abstract][Full Text] [Related]
6. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant.
Hoever P; de Haas S; Winkler J; Schoemaker RC; Chiossi E; van Gerven J; Dingemanse J
Clin Pharmacol Ther; 2010 May; 87(5):593-600. PubMed ID: 20376002
[TBL] [Abstract][Full Text] [Related]
7. Orexin receptor antagonism: an ascending multiple-dose study with almorexant.
Hoever P; de Haas SL; Dorffner G; Chiossi E; van Gerven JM; Dingemanse J
J Psychopharmacol; 2012 Aug; 26(8):1071-80. PubMed ID: 22695489
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem.
Dingemanse J; Cruz HG; Gehin M; Hoever P
J Pharm Sci; 2014 May; 103(5):1548-56. PubMed ID: 24604243
[TBL] [Abstract][Full Text] [Related]
9. Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects.
Dingemanse J; Hoever P
Drugs R D; 2013 Jun; 13(2):145-51. PubMed ID: 23737453
[TBL] [Abstract][Full Text] [Related]
10. Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects.
Hoch M; Hoever P; Zisowsky J; Priestley A; Fleet D; Dingemanse J
Pharmacology; 2012; 89(1-2):53-7. PubMed ID: 22302127
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects.
Dingemanse J; Charef P; Black J; Gouws C
Biomed Pharmacother; 2021 Jan; 133():110955. PubMed ID: 33190032
[TBL] [Abstract][Full Text] [Related]
12. Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist.
Shakeri-Nejad K; Hoch M; Hoever P; Dingemanse J
Eur J Pharm Sci; 2013 Aug; 49(5):836-44. PubMed ID: 23770377
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
[TBL] [Abstract][Full Text] [Related]
14. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
Black J; Pillar G; Hedner J; Polo O; Berkani O; Mangialaio S; Hmissi A; Zammit G; Hajak G
Sleep Med; 2017 Aug; 36():86-94. PubMed ID: 28735928
[TBL] [Abstract][Full Text] [Related]
16. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia.
Neubauer DN
Curr Opin Investig Drugs; 2010 Jan; 11(1):101-10. PubMed ID: 20047164
[TBL] [Abstract][Full Text] [Related]
17. Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study.
Roth T; Black J; Cluydts R; Charef P; Cavallaro M; Kramer F; Zammit G; Walsh J
Sleep; 2017 Feb; 40(2):. PubMed ID: 28364509
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tolerability of almorexant in Japanese and Caucasian healthy male subjects.
Hoch M; Hoever P; Alessi F; Marjason J; Dingemanse J
Pharmacology; 2011; 88(3-4):121-6. PubMed ID: 21865769
[TBL] [Abstract][Full Text] [Related]
19. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults.
Nichols AI; Abell M; Chen Y; Behrle JA; Frick G; Paul J
Int Clin Psychopharmacol; 2013 Mar; 28(2):99-105. PubMed ID: 23221858
[TBL] [Abstract][Full Text] [Related]
20. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
Hoch M; Hoever P; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
